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Abstract 
Recommendations for statin use for primary prevention of coronary heart disease (CHD) are 
based on estimation of the 10-year CHD risk. It is unclear which risk algorithm and guidelines 
should be used in European populations. Using data from a population-based study in 
Switzerland, we first assessed the 10-year CHD risk and the eligibility for statins in 5683 
women and men aged 35-75 years without cardiovascular disease, comparing the 
recommendations by the European Society of Cardiology (ESC) without and with 
extrapolation of the risk to age 60 years, the International Atherosclerosis Society (IAS) and 
the US Adult Treatment Panel III (ATP-III). The proportion of participants classified as high-
risk for CHD was 12.5% (15.4% with extrapolation), 3.0% and 5.8%, respectively.  The 
proportion of participants eligible for statins was 9.2% (11.6% with extrapolation), 13.7% and 
16.7%, respectively. Assuming full compliance to each guidelines, the expected relative 
reduction in CHD deaths in Switzerland over a 10-year period would be 16.4% (17.5% with 
extrapolation), 18.7% and 19.3%, respectively; the corresponding number needed to treat to 
 1
Nanchen D, Chiolero A, Cornuz J, Marques-Vidal PM, Firmann M, Mooser V, Paccaud F, Waeber G, Vollenweider P, Rodondi N. 
Cardiovascular risk estimation and eligibility for statins in primary prevention comparing different strategies. The American 
journal of cardiology 2009;103(8):1089-95 
 
prevent one CHD death would be 285 (340 with extrapolation), 380 and 440, respectively. In 
conclusion, the proportion of individuals classified as high-risk for CHD varied over a 5-fold 
range between recommendations. Following the IAS and the ATP-III recommendations might 
prevent more CHD deaths at the cost of higher numbers needed to treat compared to ESC 
guidelines. 
 
Key words: cardiovascular disease, modeling study, risk algorithms, statin prescription 
guidelines 
 
 
 
 
Introduction 
 
The primary prevention of cardiovascular disease (CVD) can be achieved through population-
based strategies or individualized management of risk factors1. The latter require the proper 
identification of patients at high-risk of CVD for whom treatment –e.g., by lipid lowering 
drugs- is recommended and for whom a high benefit is expected2. Three risk algorithms and 
corresponding guidelines are used in European countries to help physicians identify patients 
requiring lipid lowering drugs: the SCORE algorithm3 of the European Society of Cardiology 
(ESC)4, the PROCAM algorithm5 of the International Atherosclerosis Society (IAS)6 and the 
Framingham risk score (FRS) from the U.S. Adult Treatment Panel III (ATP-III)7. However, 
the risk algorithms might not adequately estimate individual risk. For instance, the FRS/ATP-
III overestimated coronary heart disease (CHD) risk in several European populations8. It 
remains unclear which risk algorithm and guidelines should be used9. Using data from a large 
population-based study in Switzerland, we compared the proportions of adults classified as 
high-risk and the proportions eligible for statin treatment following three risk algorithms and 
guidelines (SCORE/ESC, PROCAM/IAS and FRS/ATP-III). We also estimated the number 
of CHD events prevented and the corresponding number needed to treat (NNT) to avoid one 
CHD event over 10 years in the Swiss population aged 35-75 years, if the respective risk 
algorithm and guidelines were applied. 
 
 
Methods 
 
Our study was based on the analyses of the data of a cross-sectional, population-based study 
conducted in Switzerland, the “Cohorte Lausannoise” Study (CoLaus Study)10,11. The CoLaus 
Study was designed to investigate the prevalence and genetic determinants of CVD risk 
factors in a random sample of all Caucasian adults aged 35-75 years living in the city of 
Lausanne, Switzerland. The Institutional Review Board in Lausanne approved the protocol. 
All participants gave written informed consent. From the initial random sample, the 
participation rate was 41%10. Of the 6187 participants of the CoLaus study, we excluded 397 
with CVD, defined as self-reported diagnosis of angina, myocardial infarction, stroke, 
peripheral arterial disease or history of coronary revascularization. A further 107 participants 
(1.7%) with missing data were also excluded. Thus, the final sample of this analysis consisted 
of 5683 participants (2621 men and 3062 women).  
All participants were interviewed and examined at the Department of Ambulatory Care and 
Community Medicine in Lausanne between 2003 and 2006. Weight and height were 
measured and body mass index (BMI) was calculated. After an overnight fast, lipids and 
glucose were measured as previously described11. Blood pressure was measured three times 
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on the left arm as previously described12. The last two blood pressure readings were averaged 
and considered in the present analysis. Statins and antihypertensive drugs use was assessed 
after participants brought all current medications, including over-the-counter drugs. 
Participants were classified as never, former or current smoker based on self-reported 
smoking habits. Diabetes was defined as self-reported medical diagnosis or using any 
hypoglycemic medication. Sensitivity analyses using level of blood glucose to define diabetes 
rather than self-reported diagnosis gave similar risk estimates (data not shown). 
We used the PROCAM5 and the FRS7 algorithms to estimate the 10-year risk for CHD death 
and myocardial infarction. According to the ATP-III guidelines7, high-risk was defined as a 
CHD risk ≥ 20% (Appendix Table). We used the SCORE algorithm for low risk countries to 
compute the 10-year fatal CVD risk3, including a minor correction suggested by one of the 
authors of the SCORE paper (Fitzgerald AP, personal communication)13. The new modified 
SCORE algorithm is more accurate, yielding modest differences in risk classification when 
compared to the original risk algorithm (data not shown). In the SCORE/ESC guidelines4, the 
high-risk category was defined as a 10-year risk ≥ 5% for fatal CVD, which include CHD, 
ischemic stroke and peripheral arterial disease. The guidelines also provide a list of medical 
priorities, including markedly raised levels of single CVD risk factors, and suggest classifying 
participants with one of these priorities as being high-risk (Appendix Table). Moreover, to 
better communicate the risk of individuals aged 35 to 60 years, SCORE/ESC guidelines 
recommend extrapolation of their baseline risks as they were 60 years old4. Following the 
standard procedure for the risk estimation with SCORE/ESC, we modeled the risk in 
individuals younger than 60 years as if they were 60 years old to generate estimates of the 
SCORE algorithm with extrapolation. Because the upper age limit of the PROCAM and 
SCORE algorithms is 65 years, we used the risk prediction of age 65 for participants aged 66 
years or older, similar to a previous study14. In contrast with FRS/ATP-III and SCORE/ESC, 
in which patients with diabetes are considered like patients with a previous CHD event, in 
PROCAM/IAS diabetic patients are incorporated into the risk algorithm and are not directly 
classified as high-risk. As no PROCAM risk algorithm specific for women was available, we 
adapted estimates of the PROCAM algorithm for women considering that the absolute CHD 
risk in non-diabetic women was 4-fold lower compared with men of the same age5. A similar 
4.5-fold risk difference between gender was found in the German Monica cohort15. 
Consequently,  a rough risk prediction for women was done by dividing the risk in men by 
four for all age categories, except that the risk for diabetic women was considered as equal to 
the risk for diabetic men of the same age in the PROCAM study16. To ensure comparability, 
identical thresholds to define categories of risk factors were used for each risk algorithm. 
We used the most recent guidelines from the ESC4, IAS6 and ATP-III7 with the corresponding 
algorithm, respectively SCORE3, PROCAM5 and FRS7, to define the LDL levels at which to 
consider statin treatment (Appendix Table). In general, the vast majority of dyslipidemic 
patients are treated by statins17 and only 0.8% of participants in our study were treated by 
fibrates. Therefore, we did not consider other lipid lowering drugs in this analysis. 
The proportions of individuals classified as high-risk and individuals eligible for statins, 
above those already treated, were assessed according to 10-year age categories and gender. To 
assess differences between the risk algorithms, we used the assumption that a 10-year risk of 
fatal CVD ≥ 5% corresponds to a 10-year risk of fatal or non-fatal CHD > 20%4. We used 
Kappa statistics to assess the agreement between guidelines to detect eligible adults for 
statins. The clinical impact of each risk algorithm/guidelines in the Swiss population aged 35-
75 years without CVD was simulated by estimating the number of CHD deaths and first 
myocardial infarction potentially prevented over 10 years12 and the number needed to treat 
(NNT) by 10-year statin treatment to prevent one CHD death or the first myocardial infarction 
over 10 years, following the methodology proposed by Manuel et al18. First, we estimated the 
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number of eligible persons for statins in the Swiss population aged 35-75 without CVD, 
applying the results from the CoLaus study to the Swiss population, using data from the Swiss 
Federal Statistical Office and the 6.4% prevalence of CVD in the CoLaus study10. Second, in 
all age categories, we estimated the effect of increased statin use (from current use to full 
compliance) on the number of CHD deaths and first myocardial infarction averted using the 
same success proportion of 29.2% with statins in primary prevention19. The efficacy of statins 
in primary prevention may vary according to various baseline risks and characteristics. 
Therefore, we assumed a large 95% CI for statin benefit (95% CI: 16.7%-39.8%)19 that 
included all relative risks according to various characteristics of participants, such as gender 
or diabetes20.  CHD death rates were based on the Swiss Federal Statistical Office, 
considering that 30% of CHD deaths occur in subject without history of CHD21. First 
myocardial infarction incidence rates in Switzerland were based on local data22 from the 
Monica study15 that were available only for men. Third, using the number of CHD events 
potentially adverted and the number of eligible for statin treatment in the Swiss population, 
we estimated the NNT to avoid one CHD event over a 10-year period.  
 
 
Results 
 
The characteristics of the 2621 men and 3062 women are presented in Table 1. Some 9.7% of 
men and 7.2% of women reported the prescription of statin. The proportion of hypertensive 
individuals, diabetics and statin users increased with age, in contrast to current smokers who 
were more numerous in middle-aged than older-aged categories. The proportion of 
participants classified as high-risk by sex- and age-categories, according to each risk 
algorithm, is indicated in Figure 1.  Some 18.7% of men were classified as high-risk 
according to SCORE/ESC (25.0% with extrapolation to age 60), 5.9% according to 
PROCAM/IAS, and 9.0% according to FRS/ATP-III. Percentages of women classified as 
high-risk were 7.1% according to SCORE/ESC (7.2% with extrapolation to age 60), 0.5% 
according to PROCAM/IAS, and 3.1% according to FRS/ATP-III. Differences between 
scoring systems were particularly important among older adults. A particularly low 
percentage of women were found to be classified as high-risk with the PROCAM/IAS 
algorithm, probably related to the rough assumption that the non-diabetic women’s risk was 
25% of the men’s risk, without such data in women older than 65 years. Sensitivity analyses 
assuming an identical risk in non-diabetic men and women older than 65 years increased 
modestly the total proportion of  women classified as high-risk with the PROCAM/IAS from 
0.5% to 1.9% and the total proportion of individuals (women and men) classified as high-risk 
from 3.0% to 3.7%. For women, the SCORE/ESC with or without extrapolation to age 60 
yielded similar risk estimations, as the vast majority of women was classified as high-risk 
based on the priority list without using the algorithm (data not shown). 
The proportions of individuals eligible for statins according to each risk algorithm/guidelines 
or currently under statin treatment are indicated in Figure 2. The proportions of eligible (and 
untreated) men were 13.5% according to SCORE/ESC (18.8% with extrapolation to age 60), 
19.9% according to PROCAM/IAS and 24.2% according to FRS/ATP-III. The proportions of 
eligible women were 5.4% according to SCORE/ESC (5.5% with extrapolation to age 60), 
8.4% according to PROCAM/IAS and 10.3% according to FRS/ATP-III. With SCORE/ESC, 
all individuals eligible for statins were among adults classified as high-risk. In contrast, most 
men for whom statin treatment was recommended according to PROCAM/IAS and 
FRS/ATP-III were in the intermediate risk category and most women were in the low risk 
category. Discrepancies in eligibility between guidelines were higher in adults under 65 years 
(Appendix Figure).  Agreement for the eligibility was moderate between SCORE/ESC and 
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PROCAM/IAS (Kappa =0.43 for men and women) and high between PROCAM/IAS and 
FRS/ATP-III (Kappa=0.80 for men, 0.88 for women).  
The number of first CHD events potentially prevented is indicated in Table 2 and Figure 3. 
The expected number of CHD deaths in the Swiss population free of CHD aged 35-75 over 10 
years was 5540 for men and 1750 for women. The expected number of first myocardial 
infarction by Swiss men free of CHD aged 35-75 over 10 years was 37 555. For both sexes, 
the application of SCORE/ESC –assuming full compliance- could potentially reduce 16.4% 
(95% CI: 9.4%-22.3%) of the 7293 CHD deaths expected over 10 years. Some 17.5% 
(10.0%-23.9%) would be obtained with the application of SCORE/ESC with extrapolation, 
18.7% (10.4%-24.9%) with the application of  PROCAM/IAS and up to 19.3% (11.0%-
26.3%) with the application of FRS/ATP-III. In men, the proportions of first myocardial 
infarction averted were similar to the proportions of deaths avoided according to each risk 
algorithm/guidelines. The greatest difference between statin prescription guidelines in CHD 
events reduction (CHD deaths or myocardial infarctions) appeared among individuals aged 
less than 65 years. The estimated NNT to avoid one CHD event with 10-year statin treatment 
over a 10-year period according to gender- and age-categories using each risk 
algorithm/guidelines are indicated in Table 2 and Figure 3. The estimated total Swiss 
population aged 35-75 years without CVD was 1 786 900 for men and 1 835 000 for women. 
In both sexes, for the prevention of CHD deaths, the lowest NNT 285 (95% CI: 210-500) was 
obtained applying the SCORE/ESC. The NNT was 340 (250-590) applying SCORE/ESC with 
extrapolation; 380 (280-670) applying PROCAM/IAS, and 440 (330-780) applying 
FRS/ATP-III. The estimated NNT to prevent a first myocardial infraction in men ranged from 
40 (30-70) applying SCORE/ESC to 60 (40-100) applying FRS/ATP-III (Table 2). 
 
Discussion 
In a population-based study in Switzerland, we found that SCORE/ESC classified a greater 
number of men and women as high-risk than PROCAM/IAS and FRS/ATP-III, especially if 
they were aged 55 years or more. However, a greater number of participants were eligible for 
statins applying PROCAM/IAS and FRS/ATP-III compared to SCORE/ESC, especially if 
they were middle-aged. Whereas ESC guidelines target only individuals classified as high-
risk, PROCAM/IAS and FRS/ATP-III guidelines recommend statins also in intermediate and 
low risk individuals of CHD. As a result, the PROCAM/IAS and FRS/ATP-III strategies 
could potentially avoid a larger number of CHD events over 10 years in at the cost of a higher 
NNT compared to SCORE/ESC.  
Risk assessment algorithms might not be accurate to properly identify the high-risk 
individuals due to differences in the prevalence of CVD risk factors between populations. We 
showed that, when applied to the same population, different risk algorithms used in Europe 
lead to large differences in CHD risk estimation. Similar to previous reports23,24, our results 
confirm the fact that SCORE/ESC classifies as high-risk a large proportion of individuals, 
particularly from age 55 years onwards. Moreover, the extrapolation of the risk to age 60 
years as proposed with SCORE/ESC accentuates the proportion of middle-aged men 
classified as high-risk. The difference is substantial compared to other guidelines. As the 
guidelines for drug prescription in primary prevention of CVD base their recommendations on 
those risk estimations4,25, the choice of the risk algorithm has major clinical and public health 
implications.  
Following a high-risk strategy, the SCORE/ESC guidelines recommend statins in adults 
classified as high-risk only4, while PROCAM/IAS6 and FRS/ATP-III7 guidelines also target 
individuals with intermediate and low CHD risk, depending on their LDL levels. Our results 
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show that the percentage of participants eligible for statins with the SCORE/ESC high-risk 
strategy was lower than with the PROCAM/IAS or FRS/ATP–III guidelines, despite the large 
number of subjects classified as high-risk according to SCORE/ESC. These differences of 
eligibility between strategies were particularly evident among middle-aged adults, maybe 
because low risk individuals and young individuals were not eligible for statins according to 
the SCORE/ESC high-risk strategy. Agreement was good between PROCAM/IAS and 
FRS/ATP-III; these two guidelines have similar CHD risk and LDL-cholesterol thresholds for 
statin prescription, except that, with PROCAM/IAS6, diabetic patients are not directly 
considered as high-risk in low risk population like Switzerland. 
The absolute benefits of a preventive intervention are greater in individuals with a higher 
CVD risk2,9 and the vast majority of myocardial infarction appears at advanced age. 
Therefore, older adults have greater absolute benefits of statins in primary prevention. 
However, our results show that broader statin prescription strategies such as PROCAM/IAS 
and FRS/ATP-III could avoid more first CHD events over ten years than high-risk strategies 
such as SCORE/ESC especially among individuals younger than 65 years. In the Swiss 
population, a strategy targeting also low risk individuals would prevent more CHD events, 
because the number of CHD events in relatively young adults is large: 24 780 first myocardial 
infarctions22 were reported over the last 10 years among Swiss men aged 35-64 years. 
However, such a strategy implies the prescription of statins to a large fraction of the 
population and as a result a high NNT. Moreover, the consequences of prescribing lifelong 
statins to young individuals are unknown26. Previous studies comparing the efficacy of 
different statin prescription guidelines have shown contradictory results. Because of 
differences in the methodology and variations in the distribution of risk factors in the 
populations studied, comparisons with our results are limited: two studies were not 
population-based27,28, one studied only men aged 49-65 years and excluded diabetics29, and 
another used European guidelines in a North American population18.  
Our study has several limitations. Analyses were based on cross-sectional data from the 
CoLaus study, yielding only a comparison of individuals’ risk estimates. The performance 
and accuracy of the different algorithms could not be prospectively examined. Because of the 
modeling design of the study, we used several assumptions to estimate the number of CHD 
expected and potentially prevented and the NNT. For non-diabetic women aged 35 to 75 
years, risk estimation with the PROCAM algorithm was based on a division of the men’s risk 
by 4. This estimation was shown to be valid only for non-diabetic women aged 45 to 65 
years5. As no PROCAM data are available for women older than 65 years, risk estimates in 
women older than 65 years with the PROCAM algorithm are uncertain. However, sensitivity 
analyses considering an equal risk between women and men older than 65 years yielded only 
modest changes in the proportions of individuals classified as high-risk. Consistency, caution 
must be observed when interpreting results for individuals aged 65 or more, as SCORE3 and 
PROCAM5 are not validated for adults aged over 65 years. Moreover, outcomes for risk 
estimation were different according to the algorithm used: SCORE estimates cardiovascular 
death3 whereas PROCAM and FRS estimate fatal or non-fatal CHD5,7. The choice of the best 
outcome for risk estimation is still controversial30 and comparing results of different risk 
algorithm estimations should be interpreted with caution. The efficacy of statins in primary 
prevention may vary according to baseline characteristics of participants, such as gender or 
diabetes, but we used a large 95% CI for statin benefit. Finally, because of the theoretical 
assumption of full compliance with statin guidelines and the large limits of uncertainty of our 
results, care should be taken not to over interpret potential differences in the number of events 
prevented and NNT between guidelines. A unique strength of the study is the use of a large 
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population-based sample in Switzerland with a standardized and well-described CVD risk 
factors assessment10,11. 
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Table 1 : Characteristics of participants. 
Age categories, years   All  35-44  45-54  55-64  65-75 
Men  (N = 2621)  (n = 839)  (n = 784)  (n = 650)  (n = 348) 
 Age (years) 51.8 ± 10.6  40.2 ± 2.7  49.6 ± 2.9  59.9 ± 2.8  69.7 ± 3.1 
 Body mass index (kg/m2) 26.4 ± 3.9  25.6 ± 3.6  26.1 ± 3.8  27.3 ± 3.9  27.3 ± 4.0 
 Systolic BP (mmHg)  131.5 ± 16.3  124.4 ± 11.6  128.9 ± 14.5  137.5 ± 16.9  143.3 ± 18.4 
 Diastolic BP (mmHg)  81.2 ± 10.7  78.2 ± 9.4  82.0 ± 10.9  83.9 ± 10.6  81.9 ± 11.8 
 Total cholesterol (mg/dl)  215 ± 39  208 ± 39  219 ± 39  220 ± 38  214 ± 38 
 HDL-cholesterol (mg/dl)  56 ± 14  55 ± 13  56 ± 14  58 ± 15  58 ± 15 
 LDL-cholesterol (mg/dl) 133 ± 35  129 ± 35  135 ± 34  135 ± 34  131 ± 34 
 Triglyceride (mg/dl) 130 ± 70  122 ± 68  137 ± 75  136 ± 69  128 ± 60 
 Diabetes mellitus 5.7% (149)  1.3% (11)  3.6% (28)  9.8% (64)  13.2% (46) 
 Current Smokers 29.2% (764)  34.9% (293)  28.2% (221)  28.3% (184)  19.0% (66) 
 Hypertension treatment 16.3% (428)  4.1% (34)  11.2% (88)  26.6% (173)  38.2% (133) 
 Statin use 9.7% (255)  3.1% (26)  7.4% (58)  15.2% (99)  20.7% (72) 
Women  (N = 3062)  (n = 853)  (n = 877)  (n = 882)  (n = 450) 
 Age (years) 53.1 ± 10.6  40.2 ± 2.8  49.8 ± 2.9  60.1 ± 2.8  69.9 ± 3.1 
 Body mass index (kg/m2) 25.0 ± 4.8  24.0 ± 4.5  24.9 ± 5.0  25.6 ± 5.0  26.0 ± 4.5 
 Systolic BP (mmHg) 124.4 ± 8.2  114.4 ± 12.2  120.8 ± 15.1  130.1 ± 18.5  139.1 ± 18.7 
 Diastolic BP (mmHg) 77.5 ± 10.6  74.6 ± 9.7  77.7 ± 0.8  79.7 ± 10.7  78.4 ± 10.1 
 Total cholesterol (mg/dl) 217 ± 40  195 ± 33  214 ± 38  229 ± 38  238 ± 37 
 HDL-cholesterol (mg/dl) 70 ± 16  68 ± 14  71 ± 17  71 ± 17  71 ± 17 
 LDL-cholesterol (mg/dl) 126 ± 36  110 ± 30   124 ± 35  136 ± 35  143 ± 34 
 Triglyceride (mg/dl) 101 ± 52  86 ± 43  98 ± 54  108 ± 51  121 ± 55 
 Diabetes mellitus 3.0% (93)  1.6% (14)  2.2% (19)  3.5% (31)  6.4% (29) 
 Current Smokers  25.2% (773)  28.1% (240)  31.4% (275)  21.8% (192)  14.7% (66) 
 Hypertension treatment 14.8% (454)  4.0% (34)  9.7% (85)  22.2% (196)  30.9% (139) 
 Statin use 7.2% (219)  0.9%  (8)  3.7% (32)  11.8% (104)  16.7%  (75) 
Nanchen D, Chiolero A, Cornuz J, Marques-Vidal PM, Firmann M, Mooser V, Paccaud F, Waeber G, Vollenweider P, Rodondi N. Cardiovascular risk estimation and eligibility for statins in primary 
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Values are reported as mean ± standard deviation or percentage (number). LDL, HDL, and total cholesterol to mmol/l, multiply by 0.0259. 
Triglycerides to mmol/l, multiply by 0.0113. 
Abbreviations: BP: blood pressure. HDL: high-density lipoprotein. LDL: low-density lipoprotein 
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Table 2. Estimates of potential benefit over 10 years on the Swiss population without cardiovascular disease aged 35-75 years, if different 
guidelines for 10-year statin treatment were fully implemented. 
 
 Eligible (and 
untreated) with 
statins, N a 
Potential CHD deaths 
adverted with statins 
over 10 years, N  
(95% CI) b 
Estimated NNT with 
statins to avoid one CHD 
death over 10 years, N 
(95% CI) 
Potential first MI 
averted with statins 
over 10 years, N  
(95% CI)  b c 
Estimated NNT with 
statins to avoid one MI 
over 10 years, N  
(95% CI) c 
Men      
SCORE/ESC 243 720 970 
(550-1320) 
250 
(180-440) 
6050 
(3460-8250) 
40 
(30-70) 
SCORE/ESC with 
extrapolation  
335 090 1050 
(600-1430) 
320 
(230-560) 
7100 
(4060-9680) 
47 
(35-83) 
PROCAM/IAS 360 350 1080 
(610-1450) 
330 
(250-590) 
7310 
(4180-9970) 
49 
(36-86) 
FRS/ATP-III 436 270 1110 
(640-1510) 
390 
(290-690) 
7700 
(4400-10 500) 
57 
(41-99) 
Women      
SCORE/ESC  96 390 225 
(130-310) 
430 
(310-750) 
NA NA 
SCORE/ESC with 
extrapolation 
97 430 230 
(130-310) 
430 
(320-750) 
NA NA 
PROCAM/IAS 14 370 280 
(150-370) 
550 
(420-990) 
NA NA 
FRS/ATP-III  189 740 300 
(170-410) 
640 
(470-1110) 
NA NA 
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Abbreviations : ESC, European Society of Cardiology;  IAS, International Atherosclerosis Society; FRS/ATP III, Framingham risk score / U.S. 
National Cholesterol Education Program’s Adult Treatment Panel III; 95% CI: 95% confidence interval; CHD, coronary heart disease; MI, 
myocardial infarction; N, number; NA, not available (see footnotes). 
a Based on CoLaus and the Swiss Federal Statistical Office data, considering 6.4% as the prevalence of cardiovascular disease in adults aged 35-
75 in the CoLaus study10. 
b The relative effectiveness of statins in avoiding coronary events was assumed to be 29.2% (95% CI, 16.7- 39.8) for all risk groups in primary 
prevention, as reported by Thavendiranathan et al19. 
c No estimation was available for women, as the Swiss Monica project did not collect outcome data for women22 and given the lack of other valid 
prospective data. 
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Appendix Table. Eligibility criteria for statin treatment according to current risk algorithms and guidelines. 
 
Guidelines Scoring system Condition Eligibility according to lipid levels 
ESC 2007 SCORE 
Diabetes or  
Priority list a or 
High-risk: 10-year risk for fatal CVD of ≥ 5%  
 with extrapolation  
to age 60 years Diabetes or 
Priority list a or 
High-risk if extrapolated to age 60 years 
Total cholesterol ≥ 190 mg/dl 
or  
LDL ≥ 115 mg/dl 
High-risk : 10-year risk for fatal or non-fatal CHD of >20% LDL ≥ 100 mg/dl 
Intermediate risk: 10-year risk of  20% - 10% LDL ≥ 130 mg/dl 
Low risk: 10-year risk < 10% and 2 or more risk factors c LDL ≥ 160 mg/dl 
IAS 2003 PROCAM b 
Very low risk: 10-year risk < 10% and 0 or 1 risk factor c LDL ≥ 190 mg/dl 
Diabetes or  
High-risk: 10-year risk for fatal or non-fatal CHD of  >20% LDL ≥ 100 mg/dl 
Intermediate risk: 10-year risk of  20% - 10% LDL ≥ 130 mg/dl 
Low risk: 10-year risk < 10% and 2 or more risk factors c LDL ≥ 160 mg/dl 
ATP-III 2001 FRS 
Very low risk: 10-year risk < 10% and 0 or 1 risk factor c LDL ≥ 190 mg/dl 
Abbreviations: ESC, European Society of Cardiology; IAS, International Atherosclerosis Society; ATP-III, U.S. National Cholesterol Education 
Program’s Adult Treatment Panel III; FRS, Framingham Risk Score; CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-
density lipoprotein; LDL, low-density lipoprotein. Total and LDL cholesterol to mmol/l, multiply by 0.0259. 
a Priority list: markedly raised levels of single factors: cholesterol ≥ 320 mg/dl; LDL ≥ 240 mg/dl or blood pressure ≥ 180/110 mm Hg. 
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b Diabetic patients are incorporated into the PROCAM algorithm and not directly classified as high-risk. 
c Risk factors: current smoking; blood pressure ≥ 140/90 mm Hg or antihypertensive medication; family history of CHD; HDL < 40 mg/dl (HDL 
≥ 60 mg/dl counts as a "negative" risk factor); men aged ≥ 45 years;  women aged ≥ 55 years. 
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Figure 1 : Percentages of participants at estimated high-risk according to various risk 
algorithms.  
a Framingham risk score / U.S. National Cholesterol Education Program’s Adult Treatment 
Panel III; bInternational Atherosclerosis Society; cEuropean Society of Cardiology. 
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Figure 2 : Percentages of participants currently under statin treatment or eligible according 
to various strategies.  
a Framingham risk score / U.S. National Cholesterol Education Program’s Adult Treatment 
Panel III; bInternational Atherosclerosis Society; cEuropean Society of Cardiology. 
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Panel A :  Estimated number of coronary heart disease (CHD) deaths potentially adverted 
and number needed to treat (NNT) to avoid one CHD death over 10 years according to 
different guidelines for 10-year statin treatment, based on a full compliance and 
extrapolated to the Swiss population without cardiovascular disease aged 35-75 years. 
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Panel B : Estimated number of myocardial infarctions potentially adverted and NNT to 
avoid one myocardial infarction in a 10-year period with full compliance to different 
guidelines for 10-year statin treatment, extrapolated to Swiss men without cardiovascular 
disease aged 35-75 years. 
a Framingham risk score / U.S. National Cholesterol Education Program’s Adult Treatment 
Panel III; bInternational Atherosclerosis Society; cEuropean Society of Cardiology. 
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